For decades, KRAS was considered an undruggable target — a mutant protein so structurally elusive that the oncology field largely moved around it rather than against it. Two early clinical studies of selective KRAS G12D inhibitors now suggest that the remaining dominant KRAS mutation family may finally be within therapeutic reach, with implications extending well beyond the initial indications into pancreatic cancer, colorectal cancer, and non-small-cell lung adenocarcinoma.
The two trials, reported in Nature Medicine, evaluated selective small-molecule inhibitors targeting the KRAS G12D variant — the most prevalent oncogenic KRAS mutation, present in roughly 12–13% of all solid tumors. Both studies demonstrated measurable clinical activity in heavily pretreated patients with advanced G12D-mutant cancers, building on the precedent established by sotorasib and adagrasib, which targeted the structurally distinct G12C variant. The G12D pocket differs from G12C in that it lacks a reactive cysteine residue, making covalent binding strategies impossible and requiring an alternative, non-covalent inhibition approach. The activity signals reported across tumor types suggest the G12D inhibitors are engaging their target with sufficient potency to produce meaningful responses in at least a subset of patients.
This development carries substantial significance for several reasons. Pancreatic ductal adenocarcinoma, one of the most lethal malignancies, carries G12D mutations in approximately 40% of cases and has historically responded poorly to every class of targeted therapy. The G12C breakthrough with sotorasib validated the broader KRAS-targeting paradigm, but G12C is rare in pancreatic cancer. G12D inhibitors, if confirmed in later-phase trials, could represent the first mechanistically direct targeted therapy for a large proportion of pancreatic cancer patients. Key caveats include the early-phase nature of both studies — response durability, resistance mechanisms, and combination strategies remain largely undefined. The field will now watch closely for Phase II data on depth and duration of response.